<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic hematopoietic stem cell transplantation following reduced-intensity stem cell transplantation (RIST) has enabled the treatment of older or medically infirm patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>; however, determining the value of RIST outcomes for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is difficult because of the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the diseases included in most trials </plain></SENT>
<SENT sid="1" pm="."><plain>To define the role of RIST in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we performed RIST for 22 consecutive patients who had de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> as classified by World Health Organization (WHO) criteria and who received an allograft with fludarabine/<z:chebi fb="0" ids="28901">busulfan</z:chebi> (Busulfex) or fludarabine/Busulfex/antithymocyte globulin (ATG) conditioning </plain></SENT>
<SENT sid="2" pm="."><plain>Nineteen patients (86.4%) achieved engraftment </plain></SENT>
<SENT sid="3" pm="."><plain>At a median follow-up of 18.9 months (range, 13.1-24.8 months), the estimated 2-year rates of overall survival, event-free survival (EFS), transplantation-related mortality, and relapse were 78.7%, 67.7%, 12.6%, and 22.5%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) greater than grade II developed in 3 patients (15.8%) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD developed in 10 patients (55.6%), none of whom received ATG as a conditioning regimen </plain></SENT>
<SENT sid="6" pm="."><plain>Variables influencing EFS were <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, marrow blasts before transplantation, and the WHO criteria </plain></SENT>
<SENT sid="7" pm="."><plain>The present study clarifies the benefits of the fludarabine/Busulfex-based conditioning regimen for de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosed according to the WHO criteria and shows that <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD appears to have a beneficial effect on survival rates, which are strongly associated with graft-versus-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects </plain></SENT>
</text></document>